Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting
Business Wire•04/11/2026•09:00 ET
0
Key Highlights
- ➤Genmab (GMAB) will present 22 epcoritamab abstracts at ASH 2026
- ➤Phase 3 EPCORE DLBCL-4 will disclose primary results for epcoritamab plus lenalidomide
- ➤Six oral presentations span earlier-line therapy and multiple B-cell malignancies
- ➤Updated EPCORE FL-1 analyses evaluate epcoritamab, rituximab, and lenalidomide in follicular lymphoma
- ➤Genmab and AbbVie continue expanding epcoritamab across monotherapy and combination regimens
Expert Statements
Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab
“The range of studies accepted for presentation at this year’s American Society of Hematology Annual Meeting reflects our commitment to exploring the full utility of epcoritamab and reinforces our confidence in epcoritamab’s potential to become a core therapy across B-cell malignancies, as a monotherapy and in combination with other medicines across lines of treatment.”
Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab
“Together with our partner AbbVie, we look forward to sharing these findings with the global hematology community and further exploring what they could mean for patients.”
Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting
* Twenty-two abstracts underscore the versatility of epcoritamab as monotherapy and in combination across multiple disease subtypes and in earlier lines of therapy
Get started
Create a free account to read the full story.